Metastatic Renal Cell Carcinoma-Pipeline Review, H2 2016

Metastatic Renal Cell Carcinoma-Pipeline Review, H2 2016


  • Products Id :- GMDHC8355IDB
  • |
  • Pages: 374
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Metastatic Renal Cell Carcinoma-Pipeline Review, H2 2016

Summary

Global Markets Direct's, Metastatic Renal Cell Carcinoma-Pipeline Review, H2 2016', provides an overview of the Metastatic Renal Cell Carcinoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Metastatic Renal Cell Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Renal Cell Carcinoma and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Metastatic Renal Cell Carcinoma

The report reviews pipeline therapeutics for Metastatic Renal Cell Carcinoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Metastatic Renal Cell Carcinoma therapeutics and enlists all their major and minor projects

The report assesses Metastatic Renal Cell Carcinoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Metastatic Renal Cell Carcinoma

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Metastatic Renal Cell Carcinoma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Metastatic Renal Cell Carcinoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Metastatic Renal Cell Carcinoma Overview 10

Therapeutics Development 11

Pipeline Products for Metastatic Renal Cell Carcinoma-Overview 11

Pipeline Products for Metastatic Renal Cell Carcinoma-Comparative Analysis 12

Metastatic Renal Cell Carcinoma-Therapeutics under Development by Companies 13

Metastatic Renal Cell Carcinoma-Therapeutics under Investigation by Universities/Institutes 17

Metastatic Renal Cell Carcinoma-Pipeline Products Glance 18

Late Stage Products 18

Clinical Stage Products 19

Early Stage Products 20

Unknown Stage Products 21

Metastatic Renal Cell Carcinoma-Products under Development by Companies 22

Metastatic Renal Cell Carcinoma-Products under Investigation by Universities/Institutes 25

Metastatic Renal Cell Carcinoma-Companies Involved in Therapeutics Development 26

Acceleron Pharma, Inc. 26

Amgen Inc. 27

Argos Therapeutics, Inc. 28

Astellas Pharma Inc. 29

Bayer AG 30

Bionomics Limited 31

Bionovis SA 32

Bristol-Myers Squibb Company 33

Cellceutix Corporation 34

Celldex Therapeutics, Inc. 35

Cerulean Pharma, Inc. 36

Dr. Reddy's Laboratories Limited 37

EirGenix Inc. 38

Eisai Co., Ltd. 39

Eli Lilly and Company 40

Exelixis, Inc. 41

Gene Techno Science Co., Ltd. 42

Genor BioPharma Co., Ltd. 43

Immune Design Corp. 44

Immunicum AB 45

Incyte Corporation 46

Mabion SA 47

MedImmune, LLC 48

Merck & Co., Inc. 49

Merck KGaA 50

Millennium Pharmaceuticals Inc 51

Mycenax Biotech Inc. 52

NewLink Genetics Corporation 53

Novartis AG 54

Oncobiologics, Inc. 55

Ono Pharmaceutical Co., Ltd. 56

Panacea Biotec Limited 57

Peloton Therapeutics, Inc. 58

Pfizer Inc. 59

Prima BioMed Ltd. 60

Rexahn Pharmaceuticals, Inc. 61

Richter Gedeon Nyrt. 62

Seattle Genetics, Inc. 63

Sevion Therapeutics, Inc. 64

Syndax Pharmaceuticals Inc 65

Taiwan Liposome Company, Ltd. 66

Tocagen Inc. 67

TVAX Biomedical, Inc. 68

Tyrogenex, Inc. 69

Metastatic Renal Cell Carcinoma-Therapeutics Assessment 70

Assessment by Monotherapy Products 70

Assessment by Combination Products 71

Assessment by Target 72

Assessment by Mechanism of Action 80

Assessment by Route of Administration 87

Assessment by Molecule Type 89

Drug Profiles 92

AGS-16C3F-Drug Profile 92

avelumab-Drug Profile 93

bevacizumab biosimilar-Drug Profile 98

bevacizumab biosimilar-Drug Profile 100

bevacizumab biosimilar-Drug Profile 101

bevacizumab biosimilar-Drug Profile 102

bevacizumab biosimilar-Drug Profile 103

bevacizumab biosimilar-Drug Profile 104

bevacizumab biosimilar-Drug Profile 105

bevacizumab biosimilar-Drug Profile 106

bevacizumab biosimilar-Drug Profile 107

bevacizumab biosimilar-Drug Profile 108

bevacizumab biosimilar-Drug Profile 109

BNC-105-Drug Profile 110

cabozantinib s-malate-Drug Profile 115

capmatinib-Drug Profile 133

CDX-014-Drug Profile 136

Cellular Immunotherapy for Metastatic Renal Cell Carcinoma-Drug Profile 137

Cellular Immunotherapy for Metastatic Renal Cell Carcinoma and Melanoma-Drug Profile 138

crizotinib-Drug Profile 139

CRLX-101-Drug Profile 146

dalantercept-Drug Profile 157

durvalumab-Drug Profile 161

emibetuzumab-Drug Profile 171

entinostat-Drug Profile 173

flucytosine ER + vocimagene amiretrorepvec-Drug Profile 180

G-305-Drug Profile 187

IMP-321-Drug Profile 189

INCAGN-1876-Drug Profile 193

Intuvax-Drug Profile 195

ipilimumab-Drug Profile 201

KM-3174-Drug Profile 209

lenvatinib mesylate-Drug Profile 220

LY-2510924-Drug Profile 231

Monoclonal Antibody Conjugate to Target G250 Antigen for Renal Cell Carcinoma-Drug Profile 233

nivolumab-Drug Profile 234

Orellanine-Drug Profile 262

panobinostat-Drug Profile 263

pazopanib hydrochloride + pembrolizumab-Drug Profile 271

pembrolizumab-Drug Profile 272

PT-2385-Drug Profile 303

radium Ra 223 dichloride-Drug Profile 305

Recombinant Protein for Oncology-Drug Profile 314

rocapuldencel-T-Drug Profile 315

RX-0201-Drug Profile 321

sapanisertib-Drug Profile 325

SGN-CD70A-Drug Profile 328

Small Molecules to Inhibit SCD1 for Metastatic Renal Cell Carcinoma-Drug Profile 329

SNX-5422-Drug Profile 330

SVN-002-Drug Profile 332

TLC-388-Drug Profile 333

trebananib-Drug Profile 335

TVI-Kidney-1-Drug Profile 339

varlilumab-Drug Profile 340

X-82-Drug Profile 346

Metastatic Renal Cell Carcinoma-Dormant Projects 349

Metastatic Renal Cell Carcinoma-Discontinued Products 354

Metastatic Renal Cell Carcinoma-Product Development Milestones 355

Featured News & Press Releases 355

Appendix 369

Methodology 369

Coverage 369

Secondary Research 369

Primary Research 369

Expert Panel Validation 369

Contact Us 369

Disclaimer 370

List of Tables

Number of Products under Development for Metastatic Renal Cell Carcinoma, H2 2016 15

Number of Products under Development for Metastatic Renal Cell Carcinoma-Comparative Analysis, H2 2016 16

Number of Products under Development by Companies, H2 2016 18

Number of Products under Development by Companies, H2 2016 (Contd..1) 19

Number of Products under Development by Companies, H2 2016 (Contd..2) 20

Number of Products under Investigation by Universities/Institutes, H2 2016 21

Comparative Analysis by Late Stage Development, H2 2016 22

Comparative Analysis by Clinical Stage Development, H2 2016 23

Comparative Analysis by Early Stage Development, H2 2016 24

Comparative Analysis by Unknown Stage Development, H2 2016 25

Products under Development by Companies, H2 2016 26

Products under Development by Companies, H2 2016 (Contd..1) 27

Products under Development by Companies, H2 2016 (Contd..2) 28

Products under Investigation by Universities/Institutes, H2 2016 29

Metastatic Renal Cell Carcinoma-Pipeline by Acceleron Pharma, Inc., H2 2016 30

Metastatic Renal Cell Carcinoma-Pipeline by Amgen Inc., H2 2016 31

Metastatic Renal Cell Carcinoma-Pipeline by Argos Therapeutics, Inc., H2 2016 32

Metastatic Renal Cell Carcinoma-Pipeline by Astellas Pharma Inc., H2 2016 33

Metastatic Renal Cell Carcinoma-Pipeline by Bayer AG, H2 2016 34

Metastatic Renal Cell Carcinoma-Pipeline by Bionomics Limited, H2 2016 35

Metastatic Renal Cell Carcinoma-Pipeline by Bionovis SA, H2 2016 36

Metastatic Renal Cell Carcinoma-Pipeline by Bristol-Myers Squibb Company, H2 2016 37

Metastatic Renal Cell Carcinoma-Pipeline by Cellceutix Corporation, H2 2016 38

Metastatic Renal Cell Carcinoma-Pipeline by Celldex Therapeutics, Inc., H2 2016 39

Metastatic Renal Cell Carcinoma-Pipeline by Cerulean Pharma, Inc., H2 2016 40

Metastatic Renal Cell Carcinoma-Pipeline by Dr. Reddy's Laboratories Limited, H2 2016 41

Metastatic Renal Cell Carcinoma-Pipeline by EirGenix Inc., H2 2016 42

Metastatic Renal Cell Carcinoma-Pipeline by Eisai Co., Ltd., H2 2016 43

Metastatic Renal Cell Carcinoma-Pipeline by Eli Lilly and Company, H2 2016 44

Metastatic Renal Cell Carcinoma-Pipeline by Exelixis, Inc., H2 2016 45

Metastatic Renal Cell Carcinoma-Pipeline by Gene Techno Science Co., Ltd., H2 2016 46

Metastatic Renal Cell Carcinoma-Pipeline by Genor BioPharma Co., Ltd., H2 2016 47

Metastatic Renal Cell Carcinoma-Pipeline by Immune Design Corp., H2 2016 48

Metastatic Renal Cell Carcinoma-Pipeline by Immunicum AB, H2 2016 49

Metastatic Renal Cell Carcinoma-Pipeline by Incyte Corporation, H2 2016 50

Metastatic Renal Cell Carcinoma-Pipeline by Mabion SA, H2 2016 51

Metastatic Renal Cell Carcinoma-Pipeline by MedImmune, LLC, H2 2016 52

Metastatic Renal Cell Carcinoma-Pipeline by Merck & Co., Inc., H2 2016 53

Metastatic Renal Cell Carcinoma-Pipeline by Merck KGaA, H2 2016 54

Metastatic Renal Cell Carcinoma-Pipeline by Millennium Pharmaceuticals Inc, H2 2016 55

Metastatic Renal Cell Carcinoma-Pipeline by Mycenax Biotech Inc., H2 2016 56

Metastatic Renal Cell Carcinoma-Pipeline by NewLink Genetics Corporation, H2 2016 57

Metastatic Renal Cell Carcinoma-Pipeline by Novartis AG, H2 2016 58

Metastatic Renal Cell Carcinoma-Pipeline by Oncobiologics, Inc., H2 2016 59

Metastatic Renal Cell Carcinoma-Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 60

Metastatic Renal Cell Carcinoma-Pipeline by Panacea Biotec Limited, H2 2016 61

Metastatic Renal Cell Carcinoma-Pipeline by Peloton Therapeutics, Inc., H2 2016 62

Metastatic Renal Cell Carcinoma-Pipeline by Pfizer Inc., H2 2016 63

Metastatic Renal Cell Carcinoma-Pipeline by Prima BioMed Ltd., H2 2016 64

Metastatic Renal Cell Carcinoma-Pipeline by Rexahn Pharmaceuticals, Inc., H2 2016 65

Metastatic Renal Cell Carcinoma-Pipeline by Richter Gedeon Nyrt., H2 2016 66

Metastatic Renal Cell Carcinoma-Pipeline by Seattle Genetics, Inc., H2 2016 67

Metastatic Renal Cell Carcinoma-Pipeline by Sevion Therapeutics, Inc., H2 2016 68

Metastatic Renal Cell Carcinoma-Pipeline by Syndax Pharmaceuticals Inc, H2 2016 69

Metastatic Renal Cell Carcinoma-Pipeline by Taiwan Liposome Company, Ltd., H2 2016 70

Metastatic Renal Cell Carcinoma-Pipeline by Tocagen Inc., H2 2016 71

Metastatic Renal Cell Carcinoma-Pipeline by TVAX Biomedical, Inc., H2 2016 72

Metastatic Renal Cell Carcinoma-Pipeline by Tyrogenex, Inc., H2 2016 73

Assessment by Monotherapy Products, H2 2016 74

Assessment by Combination Products, H2 2016 75

Number of Products by Stage and Target, H2 2016 77

Number of Products by Stage and Mechanism of Action, H2 2016 85

Number of Products by Stage and Route of Administration, H2 2016 92

Number of Products by Stage and Molecule Type, H2 2016 94

Metastatic Renal Cell Carcinoma-Dormant Projects, H2 2016 351

Metastatic Renal Cell Carcinoma-Dormant Projects (Contd..1), H2 2016 352

Metastatic Renal Cell Carcinoma-Dormant Projects (Contd..2), H2 2016 353

Metastatic Renal Cell Carcinoma-Dormant Projects (Contd..3), H2 2016 354

Metastatic Renal Cell Carcinoma-Dormant Projects (Contd..4), H2 2016 355

Metastatic Renal Cell Carcinoma-Discontinued Products, H2 2016 356

List of Figures

Number of Products under Development for Metastatic Renal Cell Carcinoma, H2 2016 15

Number of Products under Development for Metastatic Renal Cell Carcinoma-Comparative Analysis, H2 2016 16

Number of Products under Development by Companies, H2 2016 17

Number of Products under Investigation by Universities/Institutes, H2 2016 21

Comparative Analysis by Late Stage Development, H2 2016 22

Comparative Analysis by Clinical Stage Development, H2 2016 23

Comparative Analysis by Early Stage Products, H2 2016 24

Assessment by Monotherapy Products, H2 2016 74

Assessment by Combination Products, H2 2016 75

Number of Products by Top 10 Targets, H2 2016 76

Number of Products by Stage and Top 10 Targets, H2 2016 76

Number of Products by Top 10 Mechanism of Actions, H2 2016 84

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 84

Number of Products by Routes of Administration, H2 2016 91

Number of Products by Stage and Routes of Administration, H2 2016 91

Number of Products by Top 10 Molecule Types, H2 2016 93

Number of Products by Stage and Top 10 Molecule Types, H2 2016 93

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Acceleron Pharma, Inc.

Amgen Inc.

Argos Therapeutics, Inc.

Astellas Pharma Inc.

Bayer AG

Bionomics Limited

Bionovis SA

Bristol-Myers Squibb Company

Cellceutix Corporation

Celldex Therapeutics, Inc.

Cerulean Pharma, Inc.

Dr. Reddy's Laboratories Limited

EirGenix Inc.

Eisai Co., Ltd.

Eli Lilly and Company

Exelixis, Inc.

Gene Techno Science Co., Ltd.

Genor BioPharma Co., Ltd.

Immune Design Corp.

Immunicum AB

Incyte Corporation

Mabion SA

MedImmune, LLC

Merck & Co., Inc.

Merck KGaA

Millennium Pharmaceuticals Inc

Mycenax Biotech Inc.

NewLink Genetics Corporation

Novartis AG

Oncobiologics, Inc.

Ono Pharmaceutical Co., Ltd.

Panacea Biotec Limited

Peloton Therapeutics, Inc.

Pfizer Inc.

Prima BioMed Ltd.

Rexahn Pharmaceuticals, Inc.

Richter Gedeon Nyrt.

Seattle Genetics, Inc.

Sevion Therapeutics, Inc.

Syndax Pharmaceuticals Inc

Taiwan Liposome Company, Ltd.

Tocagen Inc.

TVAX Biomedical, Inc.

Tyrogenex, Inc

Metastatic Renal Cell Carcinoma Therapeutic Products under Development, Key Players in Metastatic Renal Cell Carcinoma Therapeutics, Metastatic Renal Cell Carcinoma Pipeline Overview, Metastatic Renal Cell Carcinoma Pipeline, Metastatic Renal Cell Carcinoma Pipeline Assessment

select a license
Single User License
USD 2000 INR 145100
Site License
USD 4000 INR 290200
Corporate User License
USD 6000 INR 435300

NEWSLETTER BY CATEGORY




Testimonials

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com